論文・技術情報追加のお知らせ

1. Comprehensive signal detection of delirium-associated medication using the Food and Drug Administration Adverse Event Reporting System.

多くの薬剤クラスがせん妄の独立したリスク因子

対象DB：FAERS

2. A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system.

ティボザニブの副作用をFAERSデータから解析

対象DB：FAERS

3. COVID-19 Vaccination Reporting and Adverse Event Analysis in Taiwan.

台湾のCOVID-19ワクチン接種と副反応報告の調査

対象DB：FAERS,VAERS

4. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.

セマグルチドとチルゼパチド使用による脱毛の分析

対象DB：FAERS

5. Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS).

デノスマブ（プロリア）の骨粗鬆症治療における副作用を包括的に分析

対象DB：FAERS

6. Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA Adverse Event Reporting System.

イミダゾール系抗真菌薬の使用に伴う副作用の調査

対象DB：FAERS

7. Improving Resident Physician Participation in Reporting Patient Safety and Quality Concerns.

医療過誤や事故の報告率を向上させるための、住院医の参加とフィードバックを重視した品質改善プロジェクト

対象DB：FAERS

8. A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database.

FAERSを用いたティルゼパチドに関連する重篤な有害事象の監視

対象DB：FAERS

9. Central Nervous System Adverse Reactions to Amantadine Intoxication: A Case Report and Analysis of JADER.

アマンタジンによる中枢神経系の有害反応は多岐にわたり、主に投与開始後１か月以内に現れる傾向

対象DB：JADER

10. Analysis of Allergy and Hypersensitivity Reactions to COVID-19 Vaccines According to the EudraVigilance Database.

COVID-19ワクチンの重篤なアレルギー反応頻度低く、安全性高い

対象DB：EudraVigilance

11. Intranasal esketamine and manic symptoms: A disproportionality analysis in EudraVigilance.

鼻内エスケタミンと躁病症状：EudraVigilanceでの不均衡分析

対象DB：EudraVigilance

12. Investigating in VigiBase(R) over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia.

クロザピン治療患者での肺炎/誤嚥性肺炎のリスクと管理要点

対象DB：VigiBase

13. Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors.

プロテアソーム阻害剤がPAHを誘発、特にカルフィルゾミブに注意

対象DB：VigiBase

14. Development and internal validation of a clinical prediction model to predict independence in daily living at discharge for patients with heart failure: analysis using a Japanese national inpatient database real-world dataset.

心不全患者のADL自立予測モデルを開発

対象DB：DPC

15. Effect of Morphine Used to Relieve Dyspnea Due to Heart Failure on Delirium.

心不全による呼吸困難に使用するモルヒネは譫妄の発症に影響しない

対象DB：DPC

16. Children with medical complexity receiving home healthcare devices in Japan: a retrospective cohort study.

日本でHHD使用の子供が増加、酸素が最多

対象DB：NDB

17. Trends in inpatient orthopedic surgery during the COVID-19 pandemic in Japan: a nationwide data study.

COVID-19で日本の整形外科手術が30%減少

対象DB：NDB

18. Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study.

CVD予防で改善も、全体負担は高く社会経済格差も顕著

対象DB：CPRD

19. "Application of five different strategies to define a cohort of patients with knee osteoarthritis in a large primary care database".

KOA患者コホート定義で正確な罹患率算出

対象DB：CPRD

20. Assessing the uptake of incentivised physical health checks for people with serious mental illness: a cohort study in primary care.

QOF導入で精神疾患患者の健康チェック向上

対象DB：CPRD

21. Potential interactions between medications for rate control and direct oral anticoagulants: population-based cohort and case-crossover study.

DOACとアミオダロン等併用で死亡リスク増加

対象DB：CPRD

22. Epidemiological, clinical and economic burden of alopecia areata in Spain: a real-world retrospective study. The PETALO study.

スペインにおける円形脱毛症は成人に多く、治療に課題

対象DB：THIN